Zhejiang Jiuzhou Pharmaceutical (603456.SH): The application for listing of p-toluenesulfonic acid edaravone chemical raw materials has been approved.

Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that the company has received the "Chemical raw material drug market application approval letter" for the compound benzenesulfonic acid edoxaban from the National Medical Products Administration. Benzenesulfonic acid edoxaban is an oral anticoagulant used primarily to prevent strokes and systemic embolism in patients with non-valvular atrial fibrillation, as well as to treat or prevent deep vein thrombosis and pulmonary embolism.